For $200m Astrazeneca buys Neogene, and Alaunos’s long-suffering investors can just look on.
The pharma giant leads the pulmonary arterial hypertension pipeline, but other potentially disease-modifying treatments are in the works.
With a mid-stage win in cholesterol lowering in the bag, attention turns to obesity.
Talquetamab gets top billing in Ash’s press programme, but the data raise important issues about the role of targeting GPRC5D.
NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.